Dr. Farhad Peerani

Assistant Professor

Department of Medicine

Division of Gastroenterology
    Contact details are for academic matters only.

About Me

Dr. Farhad Peerani graduated from the University of British Columbia’s medical program and completed residencies in internal medicine and gastroenterology at the University of Alberta. He pursued an advanced two-year clinical research Inflammatory Bowel Disease (IBD) Fellowship at both the University of Alberta and Mount Sinai Hospital in New York City.  This training was supported by the Canadian Institutes of Health Research and the Canadian Association of Gastroenterology Fellowship Award. He was subsequently appointed Assistant Professor of Medicine at the University of Alberta on July 1, 2016.

Dr. Peerani allocates 30 percent of his time to research focusing on various aspects of inflammatory bowel disease. He has published several peer-reviewed scientific articles and has presented on a range of research topics from endoscopic scoring systems in inflammatory bowel disease to real-world efficacy of biologic therapies.  

Leadership and Collaborations:

Dr. Peerani is the Gastrointestinal and Liver Disease Research Group IBD Clinical Trials Lead and serves as principal investigator and sub-investigator on numerous multi-center clinical trials.  He is also a member of the Canadian IBD Research Consortium.


Dr. Peerani’s research interests include studying the pathophysiology of elderly-onset IBD as well as investigating the safety, efficacy and management of various therapeutic regimens used in ageing IBD patients. Furthermore, he is also interested in better understanding the IBD phenotype in patients with primary sclerosing cholangitis.  He has authored and co-authored several manuscripts published in journals such as Inflammatory Bowel Diseases, Gastroenterology and American Journal of Gastroenterology. He was a 2017 recipient of the University Hospital Foundation Medical Research Competition for a clinical study assessing the effectiveness of a stress reduction intervention in ulcerative colitis.

Research Keywords

disease pathophysiology, drug monitoring, elderly, IBD, primary sclerosing cholangitis, safety, therapeutic efficacy